Skip to main content

Table 3 Comparison of patient in Derivation and Validation phase

From: Development and validation of a scoring system for predicting cancer patients at risk of extended-spectrum b-lactamase-producing Enterobacteriaceae infections

Total, No. (%) Derivation Validation
Cases
(ESBL-PE)
n = 265 (37)
Controls
(non-ESBL-PE)
n = 445 (63)
p ESBL-PE
n = 188 (19)
non-ESBL-PE
n = 797 (81)
p
Age, median (IQR), years 56 (39–67) 60 (47–70) 0.009 55 (38–67) 59 (45–70) 0.009
Men 148 (56) 286 (64) 0.026 80 (43) 309 (39) 0.340
Emergency room at index culture 231 (87) 425 (96) 0.000 93 (59) 405 (51) 0.850
Prolonged hospitalization (≥7 days) 119 (45) 141 (32) 0.000 72 (38) 244 (30) 0.042
Hospitalization during previous year 223 (84) 264 (59) 0,000 129 (69) 542 (68) 0.871
Immunosuppressive therapya 27 (10) 19 (4) 0.002 4 (2) 10 (1) 0.363
Chemotherapya 89 (34) 183 (41) 0.046 79 (42) 330 (41) 0.877
Invasive device at the time of cultureb 146 (55) 177 (40) 0.000 98 (52) 348 (43) 0.036
Neoplasia in remission 20 (8) 17 (4) 0.031 11 (6) 30 (4) 0.197
Neutropenia 59 (22) 68 (15) 0.019 28 (15) 97 (12) 0.313
Beta-lactam use 80 (31) 82 (18) 0,000 49 (26) 99 (12) 0.000
Isolate source
 Blood 63 (23) 86 (19) 0.384 30 (16) 154 (19) 0.651
 Urinary tract 142 (54) 272 (61) 123 (65) 485 (61)
 Surgical wound 47 (18) 68 (15) 11 (6) 62 (8)
 Skin and soft tissues 3 (1) 4 (1) 17 (9) 62 (8)
 Lower respiratory tract 10 (4) 15 (3) 7 (4) 34 (4)
Isolated microorganism
E. coli. 166 (63) 299 (67) 0.000 134 (71) 505 (63) 0.002
Klebsiella spp. 92 (35) 80 (18) 33 (18) 148 (19)
Proteus spp. 3 (1) 55 (12) 5 (3) 94 (12)
 Others 4 (2) 11 (2) 16 (9) 50 (6)
  1. a during the previous 3 months, bcentral venous catheter, dialysis catheter, surgical drains, bladder catheter, nephrostomy, nasogastric tube